Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/2/2024 | $7.00 | Outperform | Oppenheimer |
| 3/18/2024 | $6.00 | Outperform | Leerink Partners |
| 9/2/2021 | $2.00 | Overweight | Cantor Fitzgerald |
Oppenheimer initiated coverage of Regulus Therapeutics with a rating of Outperform and set a new price target of $7.00
Leerink Partners initiated coverage of Regulus Therapeutics with a rating of Outperform and set a new price target of $6.00
Cantor Fitzgerald initiated coverage of Regulus Therapeutics with a rating of Overweight and set a new price target of $2.00
SC 13G/A - Regulus Therapeutics Inc. (0001505512) (Subject)
SC 13G/A - Regulus Therapeutics Inc. (0001505512) (Subject)
SC 13G/A - Regulus Therapeutics Inc. (0001505512) (Subject)
4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
S-8 - Regulus Therapeutics Inc. (0001505512) (Filer)
10-Q - Regulus Therapeutics Inc. (0001505512) (Filer)
8-K - Regulus Therapeutics Inc. (0001505512) (Filer)
Topline data from an interim analysis of the fourth cohort of its Phase 1b Multiple-Ascending Dose (MAD) clinical trial showed continued mechanistic dose response Exploratory results of imaging-based biomarkers continued to show reduction in height-adjusted total kidney volume (htTKV) growth rate Successful End-of-Phase 1 meeting with the U.S. Food and Drug Administration (FDA) with agreement on key components of a Phase 3 single pivotal trial for potential Accelerated Approval Company to hold conference call at 8:30 a.m. ET today SAN DIEGO, Jan. 29, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovati
Continued mechanistic dose response observed following completion of 3 mg/kg dose level based on urinary biomarker analyses Percent change from baseline in PC1 and PC2 demonstrated a dose response across all doses tested, with statistical significance seen at 3 mg/kg compared to placebo Exploratory imaging analyses indicated reduction in total kidney volume in 70% of patients dosed with 3 mg/kg Fourth cohort enrollment underway Company to hold conference call at 8:30am ET today SAN DIEGO, June 24, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "R
Mechanistic dose response observed at a 2mg/kg dose level based on urinary biomarker analyses Encouraging exploratory results of imaging-based biomarkers with greatest reductions in total kidney volume seen in patients with the highest increases in PC1 and PC2 Cohort 3 fully enrolled with data readout anticipated in mid-2024; Cohort 4 screening to start in 2Q 2024 Company to hold conference call at 8:30am ET today SAN DIEGO, March 12, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced positive topline results from the second
4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
SAN DIEGO, Feb. 4, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that members of the management team will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11th at 2:40 p.m. ET. The live event and replay of the presentation will be available under "Events and Presentations" through the investor relations section of the Company's website
Topline data from an interim analysis of the fourth cohort of its Phase 1b Multiple-Ascending Dose (MAD) clinical trial showed continued mechanistic dose response Exploratory results of imaging-based biomarkers continued to show reduction in height-adjusted total kidney volume (htTKV) growth rate Successful End-of-Phase 1 meeting with the U.S. Food and Drug Administration (FDA) with agreement on key components of a Phase 3 single pivotal trial for potential Accelerated Approval Company to hold conference call at 8:30 a.m. ET today SAN DIEGO, Jan. 29, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovati
SAN DIEGO, Nov. 26, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the Company will participate in the following investor conferences: Evercore 7th Annual HealthCONx Conference: Fireside chat on Tuesday, December 3, 2024, at 3:50 p.m. ETPiper Sandler 36th Annual Healthcare Conference: Presentation on Wednesday, December 4, 2024, at 11:10 a.m. ETThe live events and replays of the presentations will be
First patient dosed in second cohort of patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) in Phase 1b Multiple-Ascending Dose (MAD) study of RGLS8429 R&D Day to discuss our ADPKD program to be held Wednesday, September 6th Strengthened leadership through appointments of Preston S. Klassen, M.D. as President and Head of Research & Development and Curtis A. Monnig, Ph.D. as Vice President of CMC SAN DIEGO, Aug. 8, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results and provided a corporate upd
SAN DIEGO, June 23, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced Preston S. Klassen, M.D., President and Head of Research & Development, has been appointed to the Company's Board of Directors. "We are delighted to have Dr. Klassen join our board during this exciting time for Regulus, as we advance the clinical development of RGLS8429 for the treatment of ADPKD," said Stelios Papadopoulos, Ph.D., Chairman
Appoints Preston S. Klassen, M.D., as President and Head of Research & Development Curtis A. Monnig, Ph.D., named Vice President of CMC SAN DIEGO, June 12, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the appointment of Preston S. Klassen M.D., M.H.S., to President and Head of Research and Development. Dr. Klassen brings over 20 years of experience in leadership roles in both large and small biopharmaceutical companies. In addition, the Company announced the appointment of Curtis A. Monnig, Ph.D., to Vice President of